Sequoia Capital China led a $100m Series B funding round in Bota Bio.

Sequoia Capital China led a $100m Series B funding round in Bota Bio, a global industrial biotechnology company. The round was joined by Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners and 5Y Capital. The new funds will be used to expand the company's global operations and build out Bota Bio's lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of the company's product pipeline in consumer goods, food, nutrition, and pharmaceutical products. "Bota Bio is rapidly delivering bio-based and biologically produced products at scale to replace fossil-fuel-based, energy-intensive products and processes with biologically produced sustainable alternatives. The Bota Bio team has developed a leading integrated platform to bring innovative and efficient solutions to market for their partners. We are confident that Bota will keep enhancing their ability to accelerate the development of bio-based products, creating more value for consumers, while contributing to sustainability on a global scale," Neil Shen, Sequoia Capital China Founding and Managing Partner.